Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C - Wikidata - awgldk - TriplyDB

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34225573

about

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.Central portalization correlates with fibrosis but not with risk factors for nonalcoholic steatohepatitis in steatotic chronic hepatitis C.Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response.Association of PNPLA3 I148M Variant With Chronic Viral Hepatitis, Autoimmune Liver Diseases and Outcomes of Liver Transplantation Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response.Deveopment of hepatocellular carcinoma in a non-cirrhotic, long-term responder to antiviral therapy, chronic hepatitis C patient: what kind of surveillance?Hepatic steatosis and hepatitis C: Still unhappy bedfellows?Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients.Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.Obesity and recurrence‐free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C.

P2860

Q26745576-867A6307-C531-41AB-9E5E-F6FCBC03D3FE Q26795750-12633AB2-99EA-4EC3-A852-7663D3694148 Q26861095-6D0A5E2E-F95E-4D88-A623-41330905D7B6 Q33731308-9F61CC66-32CB-480D-8B82-651B80A8924D Q34255487-F3EB49A5-544E-45D3-9AE8-19808F60DD35 Q34698082-79F049BC-BAE5-4D82-8EBE-52853DDA49FA Q35662485-2A5B4340-82C5-4A7C-98A6-3659E72941B4 Q35667877-0A2C38DD-9F04-45B2-94F4-11AC9B3B8AE5 Q36078430-AB207072-5792-44DF-9755-DB30F5E05440 Q36561567-0FBA12EC-838A-4CB4-AB38-0CCCA1B9C783 Q37124717-82B946ED-E2F5-4B08-A1F2-4683836DBD3A Q37647643-3B1EB698-04A6-4B07-806A-A1E398383E46 Q37825653-C730AE7F-BCCA-4D8E-ACBF-D12F01B7C276 Q38232812-984F7590-3ED6-47A6-BA62-AD839BDEC296 Q38758591-5B582405-F736-43F0-8746-D4EC482A2A11 Q39695580-F58B21F1-2D26-4197-9084-37381B6A7DA7 Q40062848-CCB24E3F-C88E-4A05-8A08-90441D60C5B3 Q41528078-B243CD31-80C2-44E2-9B62-91894DDB70A6 Q41535486-06CAC894-B604-47DA-967F-0EB8FAC96A28 Q43034847-25E2B059-F5EC-4D81-A753-8BBB071012AB Q45153118-DDAC65D9-4B53-4A7E-806A-C4DB0FD7F209 Q50531115-72284E73-383C-4334-88E5-53F5D6FEC337 Q55533192-B9402692-6A81-4881-B941-88F081984823

P2860

Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34225573

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@ast

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@en

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@nl

type

label

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@ast

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@en

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@nl

prefLabel

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@ast

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@en

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@nl

P1433

Q34225573-3BF35EF7-DA5F-4899-B91F-9EBABC323BB2

P1476

Q34225573-242B7939-EDD1-49FD-9E75-84F420C9EAAA

P2093

Q34225573-1091483F-0546-4447-9B66-3565862906AD

Q34225573-1183B6F0-ADC7-4181-B1D5-7B34B589C3A2

Q34225573-21E2C877-9380-47D6-ACBE-1BCA28672287

Q34225573-44F778DD-4D3E-4BEB-A64E-1AF55F2A28D8

Q34225573-619AACE8-17E1-4A90-B630-3050CAE3BE75

Q34225573-68B9F8CD-D881-42C0-8BD5-7143FA55A4DE

Q34225573-6C6C0FB7-7393-4724-BC47-B7075D6B8E06

Q34225573-BF0B95B8-7498-4056-976C-BD22C10225DC

P2860

Q34225573-0B4325A6-A1BC-4A8F-843E-84EE419EEC2F

Q34225573-1377C08B-2F1D-4BAD-AEAC-EE71AA3FACD2

Q34225573-14533C64-F33B-4CAF-AF78-98C1ED1E10D3

Q34225573-1B1B2A57-1006-435E-99FA-9FD722A776A2

Q34225573-2498A548-16FA-4264-9A77-B643A4780799

Q34225573-2DFB0023-6568-489F-AF47-10006969F272

Q34225573-3A9F5F0B-E747-43E6-B34B-4E505DEFBAA1

Q34225573-454ABA3B-DC76-4360-8A1B-1CF32FEBC7F4

Q34225573-497A3B22-48BD-4068-A60C-EC3507AB8E0D

Q34225573-4C6A936A-EB53-41D4-B6F6-B9C5A748DAD6

P304

Q34225573-131224C2-53E5-408D-B5D9-6EBF2FCC3960

P31

Q34225573-2CA9C874-6122-4F8D-AE04-9E353F1CBB38

P356

Q34225573-AB99E636-2992-413D-974E-BF7AB91FEFBB

P407

Q34225573-78BEDAB4-D1B6-42D8-9F40-976922A8C421

P433

Q34225573-D4CCA089-DF36-4450-9C35-4AE3C80A0F22

P478

Q34225573-3AA3C98A-A3EA-4381-B278-46C047C4DF72

P577

Q34225573-139C63CF-570A-417D-8204-87EA54DB9717

P5875

Q34225573-99D0F73C-DF46-4281-A3A4-B38C0C46CD5B

P698

Q34225573-5226C0E2-9D92-4997-903B-DD5CD352BA3F

P921

Q34225573-7C913826-39E1-40B9-B63F-0E262400F00A

Q34225573-D6DF461F-6604-4376-9263-AEA1AF5BA859

Q34225573-FDBD290F-092D-4DEF-A9C9-518B6BC9258C

P932

Q34225573-87AFDDA8-5979-4E73-83FC-7E7EAD5BE405

P356

WJG.V13.I39.5180

P1433

World Journal of Gastroenterology

P1476

Hepatic steatosis as a possibl ...... ients with chronic hepatitis C

@en

P2093

Atsushi Tanaka

http://www.w3.org/2001/XMLSchema#string

Hajime Takikawa

http://www.w3.org/2001/XMLSchema#string

Hiroko Kurihara

http://www.w3.org/2001/XMLSchema#string

Ikuo Nagashima

http://www.w3.org/2001/XMLSchema#string

Junji Shiga

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Aida

http://www.w3.org/2001/XMLSchema#string

Masaki Mikami

http://www.w3.org/2001/XMLSchema#string

Satoko Uegaki

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis

Steatosis affects chronic hepatitis C progression in a genotype specific way

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

AGA technical review on nonalcoholic fatty liver disease.

Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

P304

5180-5187

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I39.5180

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5965918

http://www.w3.org/2001/XMLSchema#string

P698

17876888

http://www.w3.org/2001/XMLSchema#string

P921

eradication of infectious diseases

P932

4171299

http://www.w3.org/2001/XMLSchema#string